Loading
Mucinous ovarian cancer is rare, usually confined to one large ovary at diagnosis and cured by surgery. Its genetics resemble bowel cancer more than ovarian cancer, and pathologists must first rule out a spread from the gut before making the diagnosis.
Primary mucinous carcinoma of the ovary is uncommon and was historically over-diagnosed because metastases from the appendix, colon, stomach and pancreas mimic it. True primary tumours carry KRAS mutations in about two thirds and HER2 amplification in a fifth, share their biology with gastrointestinal cancers and often arise from a mucinous borderline tumour. Most are stage I and treated with surgery alone or with fertility-sparing unilateral oophorectomy; appendicectomy is performed if the appendix looks abnormal. Advanced disease responds poorly to carboplatin-paclitaxel, and gastrointestinal-type regimens such as capecitabine-oxaliplatin are used by extrapolation; HER2-directed therapy is an option in amplified tumours.
About three percent of ovarian cancers once metastases from the bowel and appendix are excluded; most are large, unilateral stage I tumours that surgery cures, and the rare advanced cases respond poorly to standard ovarian regimens.
Most high-grade ovarian cancers begin at the tip of the fallopian tube; endometrial cancer lines the uterus, cervical cancer starts at the transformation zone; each drains to a different node group.
Same organ: Adenosquamous carcinoma of the cervix, Small cell neuroendocrine carcinoma of the cervix, Bartholin gland carcinoma, Vulvar melanoma, Vaginal melanoma, High-grade serous ovarian cancer, Low-grade serous ovarian cancer, Clear cell ovarian cancer, Adult granulosa cell tumour of the ovary, Ovarian cancer, Endometrial cancer, Cervical cancer, Vulvar cancer, Gestational trophoblastic neoplasia, Uterine sarcoma, Vaginal cancer, POLE-ultramutated endometrial cancer, Mismatch-repair-deficient endometrial cancer, p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer with no specific molecular profile, Advanced or recurrent endometrial cancer, Uterine carcinosarcoma, Early cervical cancer and fertility-sparing surgery, Locally advanced cervical cancer, Recurrent or metastatic cervical cancer, Platinum-sensitive ovarian cancer, Platinum-resistant ovarian cancer, HPV-associated vulvar squamous cell carcinoma, HPV-independent vulvar squamous cell carcinoma (p53-mutant), Vaginal squamous cell carcinoma (HPV-associated), Vaginal adenocarcinoma (including DES-associated clear cell adenocarcinoma), Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk), Placental-site trophoblastic tumour and epithelioid trophoblastic tumour
Unilateral salpingo-oophorectomy or hysterectomy with staging; appendicectomy if abnormal; chemotherapy usually omitted for stage IA and IB.
Cytoreduction; carboplatin-paclitaxel or gastrointestinal-type capecitabine-oxaliplatin; trastuzumab for HER2-amplified tumours in trials.
Fertility-sparing unilateral salpingo-oophorectomy with staging and close follow-up.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
The mucinous ovarian cancer page's emphasis on excluding a gastrointestinal primary, omitting chemotherapy for early expansile tumours, and considering gastrointestinal-type regimens follows this review.
Mucinous ovarian carcinoma is confirmed as a primary ovarian disease with its own biology; HER2 amplification in about a fifth of cases is a possible treatment target.
Query for this cancer: (TITLE:"Mucinous ovarian cancer" OR ABSTRACT:"Mucinous ovarian cancer" OR TITLE:"Mucinous ovarian carcinoma" OR ABSTRACT:"Mucinous ovarian carcinoma" OR TITLE:"MOC" OR ABSTRACT:"MOC") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Mucinous ovarian cancer, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Bleeding that does not stop by itself, bleeding from more than one site, or new bruising in several places or one large area.
Cold-triggered acute neuropathy: avoid cold drinks and air for days after infusion.
Possible QT prolongation. QT prolongation and torsades reported post-marketing; correct electrolytes.
Dose by Calvert formula using GFR (see the calculators).
Reduce to 65 mg/m² for CrCl below 30.
The bowel cancer regimens share low blood counts, tiredness, sickness and a sore mouth. Oxaliplatin adds cold-triggered tingling, irinotecan adds early and late diarrhoea, capecitabine adds hand-foot syndrome and needs a DPD test first, and cetuximab or panitumumab add an acne-like rash and low magnesium. The rule for all of them: ring the 24-hour number rather than wait.
See all on the product pages:CapecitabineCarboplatinOxaliplatin·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Mucinous ovarian cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.